NRx Pharmaceuticals

Company Overview

Snapshot

Founded in October 2014 by Daniel C. Javitt and Jonathan C. Javitt, NRx Pharmaceuticals operates with 11–50 employees. The company has raised a total of $176.18 million across 7 funding rounds. NRx Pharmaceuticals became public on NASDAQ in May 2021.

Business overview

NRx Pharmaceuticals is a specialized biopharmaceutical company focused on addressing high unmet medical needs in central nervous system (CNS) diseases. The company develops medicines for conditions such as severe bipolar depression with suicidality and post-traumatic stress disorder (PTSD). Its pipeline leverages a proprietary, dual-targeted mechanism of action that modulates NMDA and 5HT2A receptors, aiming to deliver breakthrough science for life-threatening diseases.

Strategic signal

In September 2025, NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, completed the acquisition of Dura Medical, marking an initial step in building a network of interventional psychiatry clinics. This strategic move signals NRx Pharmaceuticals' intent to expand its reach and integrate its pharmaceutical developments with clinical care, potentially accelerating patient access to its therapies and broadening its market footprint in mental health treatment.

Company Intelligence Q&A

What was a significant recent strategic development for NRx Pharmaceuticals?

In September 2025, NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, Inc., completed the acquisition of Dura Medical. This acquisition represents an initial step in establishing a network of interventional psychiatry clinics.

What recent regulatory milestone did NRx Pharmaceuticals achieve for its IV Ketamine formulation?

In September 2025, NRx Pharmaceuticals secured FDA Fast Track designation for its IV Ketamine formulation, NRX-100, for the treatment of suicidal depression. This was further expanded in September 2025 to include NRX-100 for suicidal depression.

What was the most recent funding event for NRx Pharmaceuticals?

In August 2024, NRx Pharmaceuticals announced debt financing of up to $16 million from Anson Funds.

When did NRx Pharmaceuticals go public?

NRx Pharmaceuticals became public on NASDAQ in May 2021, following a SPAC merger with Big Rock Partners Acquisition Corporation.

What regulatory approval did NRx Pharmaceuticals receive for its preservative-free ketamine product?

In September 2025, NRx Pharmaceuticals received notification of US Food and Drug Administration approval of a suitability petition for its proposed strength of preservative-free ketamine.